Zanzalintinib after Pluvicto for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called zanzalintinib in men with advanced prostate cancer (metastatic castration-resistant prostate cancer) who have already received Pluvicto treatment. The goal is to see if this drug can help slow or stop cancer growth when other hormone therapies are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread) confirmed by biopsy
- You have already received at least one dose of Pluvicto treatment
- You have not received chemotherapy specifically for your current advanced cancer state
- You are in reasonably good health (ECOG performance status 0–2: able to do light activities or bedbound less than 50% of the day)
- Your blood counts, kidney function, and liver function are adequate based on recent lab tests
- You have recovered from side effects of any prior cancer treatments (side effects are grade 1 or mild, or your doctor approves grade 2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called zanzalitinib in men whose prostate cancer has spread and stopped responding to standard hormone treatments. The drug works differently than previous treatments and may help slow or shrink the cancer.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
Hear when a new mCRPC (Metastatic Castration-resistant Prostate Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.